Mast Cell Activation Syndrome: Improved Identification byCombined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 6, 2014, Pages 775-778

  Ravi, Anupama ^a   Butterfield, Joseph ^a   Weiler, Catherine R ^a  

^a MAYO CLINIC   (United States)

Author keywords

11 Prostaglandin F2 ; Mast cell; Mast cell activation syndrome; Tryptase

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; TELE METHYLHISTAMINE; TRYPTASE; BIOLOGICAL MARKER; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; DIARRHEA; ENZYME BLOOD LEVEL; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPATHOLOGY; MALE; MAST CELL; MAST CELL ACTIVATION SYNDROME; NAUSEA AND VOMITING; PRURITUS; RETROSPECTIVE STUDY; URTICARIA; AGED; BLOOD; BLOOD EXAMINATION; DEGRANULATION; DRUG EFFECTS; ENZYMOLOGY; MASTOCYTOSIS; MIDDLE AGED; PREDICTIVE VALUE; SYNDROME; TREATMENT OUTCOME; UNITED STATES; URINALYSIS; URINE; YOUNG ADULT;

ADULT; AGED; ASPIRIN; BIOLOGICAL MARKERS; CELL DEGRANULATION; CYCLOOXYGENASE INHIBITORS; DINOPROST; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; MINNESOTA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME; TRYPTASES; URINALYSIS; YOUNG ADULT;

EID: 84923135398     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.06.011     Document Type: Article

References (17)

1. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. JAllergy Clin Immunol 2010, 126:1099-1104.e4.
2. Hogan A.D., Schwartz L.B. Markers of mast cell degranulation. Methods 1997, 13:43-52.
3. Awad J.A., Morrow J.D., Roberts L.J. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. JAllergy Clin Immunol 1994, 93:817-824.
4. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
5. Taba Y., Sasaguri T., Miyagi M., Abumiya T., Miwa Y., Ikeda T., et al. Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase expression in vascular endothelial cells. Circ Res 2000, 86:967-973.
6. Luna-Gomes T., Magalhaes K.G., Mesquita-Santos F.P., Bakker-Abreu I., Samico R.F., Molinaro R., et al. Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation. JImmunol 2011, 187:6518-6526.
7. Tanaka K., Ogawa K., Sugamura K., Nakamura M., Takano S., Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. JImmunol 2000, 164:2277-2280.
8. Shimura C., Satoh T., Igawa K., Aritake K., Urade Y., Nakamura M., et al. Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin. Am J Pathol 2010, 176:227-237.
9. Butterfield J.H. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2010, 92:73-76.
10. Lee M.J., Akin C. Mast cell activation syndromes. Ann Allergy Asthma Immunol 2013, 111:5-8.
11. van der Donk E.M., Blok W., Kok P.T., Bruijnzeel P.L. Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects. Prostaglandins Leukot Essent Fatty Acids 1991, 44:11-17.
12. Kettelhut B.V., Berkebile C., Bradley D., Metcalfe D.D. Adouble-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. JAllergy Clin Immunol 1989, 83:866-870.
13. Valent P., Akin C., Escribano L., Fodinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
14. Hamilton M.J., Hornick J.L., Akin C., Castells M.C., Greenberger N.J. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. JAllergy Clin Immunol 2011, 128:147-152.e2.
15. Butterfield J.H., Weiler C.R. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008, 147:338-343.
16. Butterfield J.H. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009, 88:122-124.
17. Picard M., Giavina-Bianchi P., Mezzano V., Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther 2013, 35:548-562.